The gene expression signature associated with TP 53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under‐expression of TP 53 and other genes on chromosome 17p

In chronic lymphocytic leukaemia ( CLL ), TP 53 mutation and deletion are strongly associated with one another and with adverse clinical outcome. Mutant TP 53 protein typically accumulates to high levels and has been reported to have transcriptional regulatory activity distinct from that of wild‐typ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2013-01, Vol.160 (1), p.53-62
Hauptverfasser: Lin, Ke, Lane, Brian, Carter, Anthony, Johnson, Gillian G., Onwuazor, Obiageli, Oates, Melanie, Zenz, Thorsten, Stilgenbauer, Stephan, Atherton, Mark, Douglas, Angela, Ebrahimi, Bahram, Sherrington, Paul D., Pettitt, Andrew R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In chronic lymphocytic leukaemia ( CLL ), TP 53 mutation and deletion are strongly associated with one another and with adverse clinical outcome. Mutant TP 53 protein typically accumulates to high levels and has been reported to have transcriptional regulatory activity distinct from that of wild‐type TP 53. To investigate whether such an effect is relevant to CLL , carefully balanced primary CLL samples with or without TP 53 mutation/deletion were compared for their gene expression profiles using high‐density DNA microarrays. Ninety‐six and eight differentially expressed genes were identified, respectively, using two alternative statistical approaches with different stringencies. None of the differentially expressed genes were known to be regulated by mutant TP 53, and only four of the 67 under‐expressed genes were known transcriptional targets of wild‐type TP 53. Significantly, both approaches showed that gene under‐expression was the dominant feature of TP 53 ‐mutant CLL samples. Furthermore, a disproportionate number of the under‐expressed genes were located on chromosome 17p, the most significant being TP 53 itself. Together, these results indicate that any transcriptional regulatory effects of mutant TP 53 in CLL cells are overshadowed by the under‐expression of co‐deleted TP 53 and other genes on chromosome 17p. Our findings have implications for emerging therapeutic strategies that target mutant TP 53.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.12092